Clinical Trials
23 trialsNCT05420220 2026-05-28
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Completed
NCT05805501 2026-05-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06962787 2025-11-17
A Study of BL-B01D1+TKIĀ±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05256472 2025-03-06
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
Phase 2 Active not recruiting
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT00569946 2019-06-05
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
Phase 2 Completed
NCT00219557 2019-05-14
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pfizer
Phase 2 Completed
NCT01210495 2019-01-09
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT01441414 2019-01-08
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT00389441 2013-11-25
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00600821 2013-11-08
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
Phase 2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00735904 2013-01-03
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00386555 2012-08-09
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Arog Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed
NCT00094055 2012-06-26
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Pfizer
Phase 2 Completed
NCT00094094 2012-06-26
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00094107 2012-06-26
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Pfizer
Phase 2 Completed
NCT00071006 2012-06-08
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Pfizer
Phase 2 Completed